McKesson Ventures
  • Portfolio
  • News
    • In the News
    • Press Releases
  • Team
  • About Us
    • Our Approach
    • About McKesson
    • Contact Us

GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

by McKesson Ventures | Mar 2, 2021 | Press Releases

GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests. Providence...

Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

by McKesson Ventures | Feb 23, 2021 | Portfolio News

GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test. The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional...

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

by McKesson Ventures | Jan 11, 2021 | Press Releases

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and...

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

by McKesson Ventures | Jan 11, 2021 | Press Releases

GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study...

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

by McKesson Ventures | Sep 28, 2020 | Portfolio News

GRAIL and Illumina have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered...
Page 2 of 10«12345...10...»Last »

Recent Posts

  • CoverMyMeds Announces Acquisition of Companies RxLightning and FastAuth
  • Komodo Health Partners With Nasdaq to Deliver First Integrated Healthcare-Specialized Data Insights to the Financial Services Industry
  • Atropos Health Expands Oncology MultiModal Network in the Atropos Evidence Network with Addition of Ontada
  • Lumata Health Secures $23 Million Series B to Expand Access and Adherence to Vision-Saving Care
  • Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
McKesson Ventures
One Post Street, 21st Floor
San Francisco, CA 94104
USA

Contact Us

Cookie Settings

In the News

Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials

Lynx Closes $27 Million Oversubscribed Series A, Aims to Revolutionize Healthcare Payments and Administration

HarmonyCares Announces 2023 Results for its High Needs REACH ACO

Reimagine Care and Memorial Hermann Health System Unveil Expanded On-Demand Cancer Care Partnership

©2025 McKesson Ventures | Privacy Notice | Disclaimer
  • Follow
  • Follow